Vaccinations in Children Treated with Standard-Dose Cancer Therapy or Hematopoietic Stem Cell Transplantation
Section snippets
Vaccinations in children treated with standard-dose chemotherapy
Children treated with standard-dose chemotherapy are at increased risk of infection. However, there are few data on the precise incidence of specific infections in this population. With regard to vaccine-preventable disease, there are data demonstrating an increase in incidence and severity of Haemophilus influenzae type b (Hib), pneumococcal, measles, and varicella infections [1], [2], [3], [4].
Vaccinations in hematopoietic stem cell transplant recipients
In recent years HSCT has become increasingly used to allow the administration of potentially curative high-dose chemotherapy and radiotherapy to patients with hematologic and nonhematologic malignancies. HSCT is classified as either allogeneic or autologous. Allogeneic HSCT is the infusion of hematopoeitic stem cells (HSC) from a donor to a patient. Autologous HSCT is the reinfusion of the patient's own HSC. HSCT procedures vary; the source of HSC cells can be bone marrow, umbilical cord blood,
Summary
Children are immunosuppressed after completion of standard dose chemotherapy and after HSCT. They are at increased risk of infections, including vaccine-preventable infections. Revaccination is therefore important. After completion of standard dose chemotherapy, children should receive one dose of each childhood vaccine as per the immunization schedule of their country of residence.
HSCT recipients have extensive immune alterations and are particularly susceptible to infection with
References (84)
- et al.
Humoral immunity in pediatric patients with acute lymphoblastic leukaemia
Allergol Immunopathol (Madr)
(2003) - et al.
Humoral immunity against diphtheria, tetanus and poliomyelitis after antineoplastic therapy in children and adolescents—a retrospective analysis
Vaccine
(2000) - et al.
Immunodeficiency in long-term survivors of acute lymphoblastic leukaemia treated with Berlin-Frankfurt-Munster therapy
J Pediatr
(1995) - et al.
Factors associated with outcome after unrelated marrow transplantation for treatment of acute lymphoblastic leukaemia in children
Blood
(2002) - et al.
In vitro regulation of immunoglobulin synthesis after marrow transplantation. I. T-cell and B-cell deficiencies in patients with and without chronic graft-versus-host disease
Blood
(1981) The kinetics of immune reconstitution after human marrow transplantation
Blood
(1987)- et al.
The detection of specific antibody formation to recall antigens after human marrow transplantation
Blood
(1986) - et al.
Quantitation of T-cell neogenesis in vivo after allogeneic bone marrow transplantation in adults
Blood
(2001) - et al.
Long-term immunity to measles, mumps and rubella after allogeneic bone marrow transplantation
Blood
(1994) - et al.
Donor immunisation with pneumococcal conjugate vaccine allows early protective antibody responses following allogeneic hematopoietic cell transplantation
Blood
(2003)